Study on ALIMTA (Pemetrexed) Alone or with Cisplatin for Treating Malignant Mesothelioma

Sponsor: Eli Lilly and Company

Expanded Access
Approved for Marketing
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT00040625

Provider View

This clinical trial is testing the effects of the drug ALIMTA, either by itself or combined with Cisplatin, on patients with malignant pleural mesothelioma. The study also aims to provide ALIMTA to eligible patients.

Patient Parameters

Program Overview

The purpose of this study is to understand how the drug ALIMTA, alone or in combination with Cisplatin, affects patients with malignant pleural mesothelioma, a type of cancer affecting the lining of the lungs. The study will look at both the positive and negative effects of these treatments and aims to make ALIMTA available to patients who meet the eligibility criteria.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of malignant mesothelioma and are not eligible for surgery to cure the disease.
  • Previous chemotherapy treatment for mesothelioma is allowed.
  • Having a measurable tumor is not necessary to participate.
  • Must be in good enough health to participate in the study.
  • Must agree to and sign an informed consent form.

Exclusion Criteria

  • Have taken any experimental drugs within four weeks before joining the study.
  • Have received radiation therapy within the last two weeks.
  • Are eligible for surgery that could potentially cure the mesothelioma.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.